已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Presenting limb severity is associated with long-term outcomes after infrainguinal revascularization for chronic limb-threatening ischemia

医学 四分位间距 血运重建 截肢 危险系数 严重肢体缺血 缺血 比例危险模型 外科 回顾性队列研究 置信区间 阶段(地层学) 内科学 心肌梗塞 生物 古生物学
作者
Iris H. Liu,Rym El Khoury,Bian Wu,Warren J. Gasper,Peter A. Schneider,Jade S. Hiramoto,Shant M. Vartanian,Michael S. Conte
出处
期刊:Journal of Vascular Surgery [Elsevier BV]
卷期号:77 (4): 1137-1146.e3
标识
DOI:10.1016/j.jvs.2022.12.036
摘要

The SVS Wound, Ischemia, foot Infection (WIfI) limb staging system was established to estimate risk of major amputation in chronic limb-threatening ischemia (CLTI) and better stratify outcomes comparisons. There is little data on treatment outcomes beyond 1 year based on presenting WIfI stage.This is a single-institution retrospective study of 413 patients who underwent infrainguinal revascularization for CLTI (2011-2021) with data available for WIfI staging. Patient characteristics and outcomes were gathered from the electronic medical record. Data were analyzed based on presenting WIfI stage and initial treatment received at our center.Presenting WIfI stages were 1 to 2 (23%), 3 (27%), and 4 (50%). Index revascularization approach was endoluminal (59%), autogenous vein bypass (29%), or non-autogenous bypass (13%). Operative mortality within 30 days was 2.9% and was not associated with WIfI stage or revascularization approach. Median limb follow-up time was 502 days (interquartile range [IQR], 112-1256 days), and median survival follow-up time was 932 days (IQR, 343-1770 days). Major amputation or death occurred in 19% and 46% of patients at median times of 119 days (IQR, 28-314 days) and 739 days (IQR, 204-1475 days), respectively. WIfI stage was independently associated with major amputation (P = .001), as was initial revascularization approach (P = .01). In a Cox proportional hazards model, factors independently associated with major amputation were male sex (hazard ratio [HR], 1.4; 95% confidence interval [CI], 1.04-2.0; P = .03), diabetes (HR, 1.8; 95% CI, 1.3-2.5; P = .001), WIfI stage 4 (HR, 2.3; 95% CI, 1.5-3.5; P < .001), and non-autogenous bypass (HR, 2.9; 95% CI, 2.1-4.2; P < .001). In a Cox proportional hazards model for mortality, independently associated factors were age (HR, 1.04; 95% CI, 1.02-1.05; P < .001), end-stage renal disease (HR, 2.8; 95% CI, 1.9-4.0; P < .001), congestive heart failure (HR, 1.9; 95% CI, 1.4-2.5; P < .001), chronic obstructive pulmonary disease (HR, 1.5; 95% CI, 1.1-2.1; P = .02), and WIfI stage 4 (HR, 1.6; 95% CI, 1.04-2.2; P = .03). Among those presenting with WIfI stage 4 limbs, Kaplan-Meier estimated rates of freedom from major amputation or death at 2 years were 71% ± 3.7% and 68% ± 3.5%, respectively. In an inverse propensity weighted Cox proportional hazards model, non-white race (HR, 1.5; 95% CI, 1.01-2.2; P = .047), diabetes (HR, 2.0; 95% CI, 1.2-3.3; P = .008), Global Anatomic Staging System infrapopliteal grade (HR, 1.2; 95% CI, 1.05-1.3; P = .005), non-autogenous bypass (HR, 3.2; 95% CI, 1.9-5.3; P < .001), and endoluminal revascularization (HR, 2.6; 95% CI, 1.6-4.3; P < .001) were independently associated with major amputation in the WIfI stage 4 subgroup.Presenting WIfI stage is strongly associated with long-term risks of major amputation and death following infrainguinal revascularization for CLTI and should be used to stratify outcomes comparisons. Effective revascularization is critical in WIfI stage 4 disease, and autogenous vein bypass provides durable long-term limb preservation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
观澜完成签到 ,获得积分10
3秒前
ummmmm发布了新的文献求助10
5秒前
梦梦完成签到 ,获得积分10
5秒前
一一应助嗜蛋黄小怪布丁采纳,获得10
8秒前
9秒前
ummmmm完成签到,获得积分10
13秒前
13秒前
嘻嘻嘻发布了新的文献求助10
13秒前
momo发布了新的文献求助30
17秒前
碳酸氢钠完成签到,获得积分10
26秒前
七个丸子应助zzn采纳,获得10
34秒前
胸神恶煞完成签到 ,获得积分10
35秒前
B_lue完成签到 ,获得积分10
36秒前
36秒前
38秒前
小鹿发布了新的文献求助10
40秒前
GGKing发布了新的文献求助10
41秒前
那行laxg完成签到,获得积分10
41秒前
光子完成签到 ,获得积分10
42秒前
LeoBigman完成签到 ,获得积分10
44秒前
zzn完成签到,获得积分10
50秒前
韩擎宇完成签到 ,获得积分10
54秒前
LMBE1K完成签到 ,获得积分10
55秒前
yan完成签到 ,获得积分10
1分钟前
三叔完成签到,获得积分0
1分钟前
爱笑的山晴完成签到,获得积分10
1分钟前
Forest1sland完成签到,获得积分10
1分钟前
w1x2123完成签到,获得积分0
1分钟前
知画春秋完成签到 ,获得积分10
1分钟前
大模型应助守拙采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
YifanWang应助科研通管家采纳,获得10
1分钟前
研友_ngX12Z完成签到 ,获得积分10
1分钟前
聪明萤完成签到 ,获得积分10
1分钟前
领导范儿应助能干的烧鹅采纳,获得10
1分钟前
凡雁完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Various Faces of Animal Metaphor in English and Polish 800
Signals, Systems, and Signal Processing 610
Adverse weather effects on bus ridership 500
Photodetectors: From Ultraviolet to Infrared 500
On the Dragon Seas, a sailor's adventures in the far east 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6350447
求助须知:如何正确求助?哪些是违规求助? 8165203
关于积分的说明 17181766
捐赠科研通 5406706
什么是DOI,文献DOI怎么找? 2862640
邀请新用户注册赠送积分活动 1840257
关于科研通互助平台的介绍 1689448